IRB Policies and Procedures
Revision Approved: June 13, 2011
Section 1: POLICY
Section 2: SCOPE
Section 3: INSTITUTIONAL REVIEW BOARD (IRB)
Section 5: CATEGORIES OF REVIEW
5.01. Classification of protocols for review
5.02. No Risk Beyond Everyday Life
5.03. Risk Beyond Everyday Life
5.06. Form A Review
5.07. Form B Review
5.08. Form C Review
5.09. Review of Protocol Changes
5.10. Continuing Review
Section 6: RESEARCH REVIEW
Section 7: INFORMED CONSENT
Section 8: GUIDE FOR SUBMISSION OF APPLICATIONS
8.02. Procedure for Submitting Course-Related and Student-Conducted Research
8.03. Submission to the DRB
8.04. Submission to the IRB
8.05. Submission of Form A Applications
8.06. Submission of Form B Applications
8.07. Submission of Form C Applications
Section 9: IRB PROCEDURES
Section 10: SUSPENSION OR TERMINATION OF RESEARCH
Section 12: DEPARTMENTAL REVIEW BOARD (DRB) GUIDELINES
Section 1: POLICY
The University of Scranton (University) is committed to safeguarding the rights and welfare of human participants in all research under its sponsorship and to serving as their protector on behalf of the community of persons that comprise the University.
These policies and procedures result from the desire of the University to define its responsibilities and to comply with all applicable federal, state, and local regulations.
Principal guides for the University's human subjects review system are:
The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research[The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, April 18, 1979].
Protection of Human Subjects [Code of Federal Regulations - 45 CFR 46, revised November 13, 2001, effective December 13, 2001].
All research involving human subjects, conducted at the University or under its sponsorship at another location, must be reviewed and approved by the Institutional Review Board for Protection of Human Subjects (IRB) or its designated reviewer(s) under the policies and procedures outlined in the following document.
When reviewing research proposals, the IRB or DRB is primarily interested in safeguarding the rights and well being of the human subject and in assessing the ethical implications of the proposed procedures. The ethical principles and their translation into action:
Respect for Persons - Informed Consent,
Beneficence - Assessment of Risks and Benefits, and
Justice - Equitable Selection of Subjects,
set forth in the Belmont Report serve as the guide for the IRB/DRB's review of all research activities.
Research procedures and design may affect the use and experience of human subjects in research activities. In this context, the IRB/DRB has the responsibility to require modification or change in the design of the research, to assure that the use of human subjects is valid and the risks to the subjects are minimized. However, it is not the intention of the IRB or DRB to provide full scientific review.
In analyzing the risk/benefit ratio of a research activity, both the stated goals and the scientific merit of the research will be considered. Therefore, the research must be described to the IRB or DRB in a manner that allows adequate review of all these aspects of the research.
2.01. Activities within the scope of the Human Subjects review policy include research, development, and related activities which would normally be construed as biological, behavioral, or psychological investigations involving human subjects. The IRB is responsible for the review of all research activity that involves human subjects that is conducted
(a) at the University and its sites
(b) by any University employee or student either at University sites or elsewhere who represents him or herself to the subjects as affiliated with the University with the following exceptions:
(1) Newly employed full and part-time faculty members ongoing research projects, including but not limited to dissertation research, must provide evidence of initial and continuing IRB approval from the initiating institution.
(2) Part-time faculty members with research not initiated as a University project and not representing the University in any way must provide evidence of IRB approval from the employing or sponsoring institution.
(a) use of graphic, written, or recorded information about individuals even when this information has been collected by other institutions or investigators.
(b) investigations of prenatal life.
(c) studies or procedures utilizing organs, tissues, or bodily fluids of a human.
(d) investigations of organizations.
2.03. Institutional (internal) research is the gathering of data from University employees, students or offices which will be used solely for internal program improvement, informational or required data-collection purposes, for example:
(a) Course evaluations
(b) Surveys or other data collection methods for
(1) improving University services or procedures,
(2) ascertaining opinions, experiences or preferences of the University community,
(3) providing necessary information to characterize the University.
IRB review is not required for institutional research except when
(a) the information deals with sensitive subject matter and disclosure of the responses outside of the research could place the subject at criminal or civil liability or be damaging to the subject's reputation, employability, or financial standing. Such sensitive information could include the subject's drug or alcohol use, aspects of sexual behavior, or illegal conduct, OR
(b) it is anticipated that the data generated will be used for research, the results of which will be disseminated outside of the University community.
3.01. Members of the IRB are appointed by the Provost/Academic Vice President of the University to represent the interests of the University and the community. IRB members are ordinarily appointed for a three-year term and may be reappointed when this initial term expires. There are at least seven members of the IRB, with various backgrounds and fields of expertise, including at least one faculty representative from the humanities, natural sciences, social sciences, business and professional studies, and at least one community representative from outside of the University.
The IRB may, at its discretion, invite individuals with competence in special areas to assist in the review of issues which require expertise beyond or in addition to that available on the IRB. These individuals may not vote with the IRB.
The Research Compliance Officer shall serve as the IRB Administrator.
Research covered by this policy that has been approved by the IRB may be subject to further appropriate review and approval or disapproval by officials of the University. However, those officials may not approve the research if it has not been approved by the IRB.
The IRB Chairperson is appointed annually by the Provost from among the IRB members; responsibilities include
(a) convening and conducting meetings
(b) consulting as needed with the IRB Administrator on Form A applications (section 5.06.)
(c) reviewing additional information submitted following additional IRB review as empowered by the board.
Responsibilities of the IRB Administrator include:
(a) scheduling and sending notification of IRB meetings,
(b) disseminating meeting materials and applications in timely manner for review prior to a convened meeting,
(c) recording minutes of IRB meetings,
(d) maintaining IRB files,
(e) approving Form A applications (section 5.06.) in consultation with the IRB Chairperson if needed,
(f) notifying investigators of IRB actions,
(g) notifying IRB Chairperson and other University officials as appropriate of reported adverse events,
(h) coordinating the IRB education program.
Completion of an IRB approved education program will be required of all individuals involved in Human Subjects Research and its review including IRB members, IRB Administrator, DRB members, investigators, and research assistants (section 4.) who interact with subjects and/or have access to data which contains personal identifiers.
All persons involved in the research protocol must complete an approved education program prior to approval of protocol activity. The education program must have been completed less than 3 years prior to submission of the application. Certification must be renewed on a regular basis as defined in the IRB education program.
The IRB delegates review and approval of certain research activities to Departmental Review Boards (DRBs) in those departments which routinely conduct human subject research.
Applications for review by a DRB may be submitted only by the respective department's faculty, staff, and students.
The DRB may review research submitted on Form A (section 5.06) and Form B (5.07) in accordance with its approved written guidelines (section 12.). Form C applications may only be reviewed by the IRB. In addition, the DRB may not review research
(a) For which the IRB provides notice to the investigator or department that the IRB is exercising its oversight responsibility and requires IRB review and approval, or
(b) For which an investigator requests IRB review in addition to, or in substitution for, the departmental review process, even if this activity falls within the departmental guidelines.
Under these conditions, the DRB chair will be advised of the IRB determination and will be provided with a copy of the protocol.
For IRB purposes:
(a) Investigators are defined as all persons who contribute significantly to the design and implementation of a study protocol.
(b) Research Assistants are all persons who contribute to the implementation of the study, including interaction with subjects and/or access to data, but do not participate in the design and development of the study protocol.
Investigators at the University are entrusted with the primary responsibility for protecting the human subjects involved in their research in accordance with University policies, all applicable federal, state, and local regulations, and the code of ethics of their professions. Specific responsibilities of investigators are to:
(a) Submit an adequately prepared form to the IRB via the Office of Research and Sponsored Programs or the appropriate DRB for each research project involving human subjects.
(b) Request a continuing review if the research extends beyond the initial review period.
(c) Notify the IRB and the departmental chairperson of any injury ‑ physical, psychological, or social ‑ suffered by a subject because of his or her participation in a research activity.
(d) Retain adequate records, documents, and informed consent forms for at least three (3) years following the completion of the approved project or activity, or for a longer period as judged necessary.
(e) Maintain current certification in Human Subjects Education.
(f) Assure that all research assistants participating in the protocol receive complete training, and that an "IRB/DRB Research Assistant Training Certification" form is filed with the IRB Administrator or appropriate DRB Chairperson for each research assistant.
(a) Form A - Research involving Anonymous Surveys/Interviews/Public Observations/Pre-existing Data with No Risk Beyond Everyday Life
(b) Form B - Research involving No Risk Beyond Everyday Life and Use of Experimental Procedures (other than Surveys) or Recording the Identity of Participants
(c) Form C - Research involving Risk Beyond Everyday Life, Deception, and/or Vulnerable Participants
It means that the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.
A project may entail more than minimal risk if
(a) sensitive questions (such as sexual preferences or behavior, criminal behavior, abuse situations) are included in questionnaires or interviews,
(b) fully informed consent cannot be obtained because the procedure includes deception,
(c) fully informed consent cannot be obtained due to age or mental condition, OR
(d) there is an increased potential for coercion (for example, institutionalized persons).
Surveys, questionnaires, interviews, public observations, and pre-existing data are anonymous when no identifiers are recorded anywhere in the investigator's records, so that no individual can be connected with his/her responses.
Deception in human subjects research involves not informing the subject of all aspects of the study so that the subject is not able to give full informed consent. A study involving deception will not be approved by the IRB unless the investigator has demonstrated to the IRB that
(a) The use of deceptive techniques is justified by the study's significant prospective scientific, educational, or applied value and that effective nondeceptive alternative procedures are not feasible;
(b) Procedures in the study cannot be reasonably expected to cause physical pain or severe emotional distress; AND
(c) As early as feasible, preferably at the conclusion of their participation, but no later than at the conclusion of the data collection, the investigator will inform the subjects about the deception, and permit subjects to withdraw their data.
Form A allows for a simplified review process. The investigator may submit the application for review by the IRB Administrator or the appropriate DRB.
The University IRB has determined that research involving vulnerable populations (section 7.02) does not qualify for Form A, except for research which utilizes pre-existing data and where the investigator does not have access to identifiers of any kind.
Applications determined not to meet the criteria for Form A submission will be returned to the investigator with a full explanation and may be re-submitted on Form B or Form C as appropriate.
DRBs may review of Form B research projects conducted by their own department faculty, staff, and/or students. DRBs function in compliance with all the regulations and institutional policies applicable to the IRB and in accordance with their individual guidelines and procedures as approved by the IRB.
For investigators in departments without DRBs and investigators in departments with DRBs who request IRB review, the IRB reviews Form B research in a convened meeting.
Full review in a convened IRB meeting is required for all research projects requiring use of Form C.
Investigators must submit all proposed changes to an approved protocol for review and approval prior to instituting the change.
5.09.01 Changes to a protocol approved under Form A may be submitted to the IRB Administrator or DRB under the Form A Review procedure (section 5.04) unless the proposed changes render the project ineligible for exemption.
Such changes include (but are not limited to) submission for external funding, increase in the risk level, changing the manner of identification of the subjects, inclusion of vulnerable populations, therefore requiring submission for full IRB or DRB review.
A change is considered to be minor (non-substantive) if it does not have the potential to alter the level of risk and is an:
(a) Extension of the time of the study due to circumstances which kept the investigator from completing the project as approved,
(b) Increase or decrease in the number of subjects, within statistically valid limits,
(c) Extension of data analysis without involving more subjects, OR
(d) Change in investigator contact information in the informed consent information and written consent document.
5.09.03 Substantive changes to a Form B protocol must be submitted for full IRB or DRB review. Substantive changes to form C protocols require full IRB review. A change is considered to be substantive if it
(a) Changes any information in the informed consent information and written consent document other than investigator contact.
(b) Is likely to reduce the validity of the study, e.g., decreases the number of subjects to a level which affects the statistical validity of the research,
(c) Changes the level of risk from a lower to a higher category, e.g. from Form B to C
(d) Alters the way in which subjects are placed at risk that is beyond everyday life.
Continuing review includes review protocols on an interim basis as determined by the IRB or DRB during initial review or for renewal of approval for an additional period of time.
Based on initial review, the IRB may require review at intervals less than the normal approval period of one year. Reasons may include risk level or previous IRB violations by the investigator. Review may be conducted by 2 members of the IRB or the full IRB, as determined in initial review or based on findings.
All research protocols are approved for a maximum one year period after which renewal may be requested for an additional year.
(a) Projects originally approved as Form A may be submitted for continuation beyond the initial approval period under the Exemption from Full IRB Review procedure unless the proposed changes render the project ineligible for exemption, including (but not limited to) submission for external funding, increase in the risk level, inclusion of vulnerable populations, therefore requiring submission for Full IRB Review.
(b) Projects originally approved under Form B or C proposing no substantive changes require review and approval by 2 members of the IRB.
(c) Projects originally approved by DRB proposing no substantive change will be reviewed by the DRB.
(d) Projects originally approved by DRB proposing substantive change should be submitted to the DRB. The DRB may send the protocol for full IRB review if warranted.
(e) Application for continuation of a project originally approved by the IRB which proposes substantive change requires submission for full IRB review.
6.01. Review Criteria [45 CFR 46:111]
In order to approve research covered by this policy the IRB (and DRB) must determine that all of the following requirements are satisfied:
(a) Risks to subjects are minimized:
(1) by using procedures which are consistent with sound research design and which do not unnecessarily expose subjects to risk, AND
(2) whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes.
(b) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result. In evaluating risks and benefits, the IRB considers only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research). The IRB will not consider possible long-range effects of applying knowledge gained in the research (for example, the possible effects of the research on public policy) as among those research risks that fall within the purview of its responsibility.
(c) Selection of subjects is equitable. In making this assessment the IRB will take into account the purposes of the research and the setting in which the research will be conducted and should be particularly cognizant of the special problems of research involving vulnerable populations, such as children, prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged persons.
(d) Informed consent must be sought from each prospective subject or the subject's legally authorized representative. (Section 7)
(e) Informed consent must be appropriately documented. (Section 7.07)
(f) When appropriate,
(1) the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.
(2) there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
(g) When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, pregnant women, mentally disabled persons, or economically or educationally disadvantaged persons, additional safeguards have been included in the study to protect the rights and welfare of these subjects.
6.02. NIH-supported investigators are required to provide details of the proposed involvement of humans in the research, including the characteristics of the subject population, anticipated numbers, age ranges, and health statuses. The proposed research should specify the gender and racial/ethnic composition of the subject population, as well as criteria for inclusion or exclusion of any subpopulation. If ethnic, racial, and gender estimates and continuing review numbers are not included in the background data for a protocol, the investigators must provide a clear rationale for exclusion of this information.
Ongoing review of research activities may require random selection and review by the IRB of approved projects for assessment of the IRB/DRB activities and compliance. IRB policies and procedures (including DRBs) should be reviewed annually. Review may be accomplished by two or three members of the IRB and/or the IRB Administrator.
It is a process, not just a document. Informed consent must be obtained from every potential subject or the subject's legal representative. Fully informed consent must be documented by the investigator. Except in special circumstances described below, informed consent must be verified by a signed written consent form.
The prospective subject or representative must be given sufficient opportunity to consider whether or not to participate. The information that is given to the subject or representative must be in language understandable at the individual's level of comprehension.
Investigators have special responsibilities whenever potential subjects have circumstances which might affect their ability to give informed and voluntary consent to participate in a research project, whether or not the subject categories are included in the vulnerable populations defined in the federal regulations.
Although only certain categories of subjects are mentioned specifically in the regulations, the researcher has special responsibilities whenever the potential subjects have circumstances which might affect their ability to give informed and voluntary consent to participate in a research project. Researchers must use extreme care to respect the rights of subjects when they develop consent procedures. When written consent or assent cannot be obtained, a verbal script must be submitted with the protocol.
Permission to conduct research with children requires special attention to the child's age, ability to understand what is asked, and relationship to parents or guardians.
(a) Parental/Guardian Consent is required in writing for all minors (under the age of 18). A waiver of parental consent may be granted by the IRB if it deems that the request for waiver meets the spirit of the principles of the Belmont Report and is in accordance with the provisions of the regulations as set forth in 45 CFR 46:117 or 408(c).
(b) Adolescent (junior/senior high) Assent must be obtained in writing; the investigator should use supplementary verbal explanations when needed.
(c) Child (elementary) Assent should be obtained in a form which the child can understand. A signed assent form must be obtained from children old enough to render a signature.
(d) Very Young Child - explanations should match the level of understanding.
Risks must be enumerated to allow the patient to decide whether or not to participate. Also included should be any protections to lower the potential risk and an injury clause (see Elements of Informed Consent #9 below).
Deception in human subjects research (section 5.05) involves not informing the subject of all aspects of the study so that the subject is not able to give full informed consent. As early as feasible, preferably at the conclusion of their participation, but no later than at the conclusion of the data collection, the investigator must inform the subjects about the deception, and permit subjects to withdraw their data.
Surveys and questionnaires are "anonymous" only when the individual's identity is not recorded anywhere in the investigator's records. Requirements of informed consent can be fulfilled by instructions or a cover letter that explains (as applicable) the project, purpose and duration of participation time; how to contact the investigator for more information; a statement that assures anonymity; indication that voluntarily returning the questionnaire constitutes consent to participate.
7.06. Elements of Informed Consent [45 CFR 46:116]
In clear and non-technical language which is appropriate to the subject, subjects must be informed of:
(a) The fact that the study is research.
(b) The purposes of the research.
(c) The expected duration of the subject's participation.
(d) The procedures to be followed.
(e) Any reasonably foreseeable risks or discomforts.
(f) Any benefits to the subject or to others which may reasonably be expected from the research.
(g) Appropriate alternative procedures or courses of treatment, if any, which might be advantageous to the subject.
(h) The extent, if any, to which confidentiality of data and privacy of subjects will be maintained.
(i) For research involving more than minimal risk, whether any compensation and whether any medical treatments are available if injury occurs.
(j) Whom to contact for answers to pertinent questions about the research, subjects' rights, and research-related injury to the subject.
(k) A statement that participation is voluntary, refusal to participate will involve no penalty or loss of benefits to which the subject is otherwise entitled and the subject may discontinue participation at any time without penalty or loss of benefits to which the subject is otherwise entitled.
When appropriate, one or more of the following elements of information shall also be provided to each subject:
(a) A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) which are currently unforeseeable;
(b) Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent;
(c) Any additional costs to the subject that may result from participation in the research;
(d) The consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject;
(e) A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject;
(f) The approximate number of subjects involved in the study.
7.06.01. Exceptions/Waivers - The IRB may approve a consent procedure which does not include, or which alters, some or all of the elements of informed consent set forth above, or may waive the requirement to obtain informed consent provided the IRB documents its findings in accordance with 45 CFR 46:116 (c-e).
7.06.02. Exculpatory language may not be included in any informed consent (oral or written). Subjects or their representatives cannot be made to waive or appear to waive any legal rights, or release or appear to release the investigator, sponsor, institution, or agents from liability for negligence.
The subject or a legal representative signs a written consent document, which explains all of the elements of informed consent. Due to the individual nature of informed consent, the University IRB does not encourage the use of templates for written consent. However, samples of written consent documents are provided by the Office of Research and Sponsored Programs (ORSP) and are available on the ORS Human Subjects Research website to serve as guides for investigators.
The subject or a legal representative signs a document indicating the subject had all of the elements of informed consent explained orally and that s/he understands this description and s/he agrees to participate in the activity described. In addition, an auditor‑witness to the oral presentation must be present and must sign the consent form as "witness." A written script of the oral presentation must be approved by the IRB and will be retained as a part of the IRB records.
The IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either:
(a) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality, OR
(b) That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context.
In cases in which the documentation requirement is waived, the IRB may require that the investigator provide subjects with a written statement regarding the research. A copy of this statement must be included with the materials in the IRB application, and the investigator must certify that the subjects have been informed.
Informed consent shall comply with all requirements of the Health Insurance Portability and Accountability Act (HIPAA), PL104-191, and the Standards for Privacy of Individually Identifiable Health Information (Privacy Rule) 45 CFR 160 and 164.
The University is classified under HIPAA as hybrid entity, meaning that it has divisions which fall under HIPAA regulations and those which do not. Human subjects research is not considered health care and is therefore not a covered entity.
When using research subjects at a covered entity (e.g., hospital, clinic, doctor's office, or other health care facility), the investigator must abide by that institution's regulations, and the University's IRB will require an authorization to use protected health information (PHI) as an addendum to the consent form. Specific conditions are outlined in the regulations concerning use and disclosure of PHI in research. A researcher may enter into a "data use agreement (defined in the regulations)" with a covered entity allowing access to a limited data set which excludes specified direct identifiers, or the entity may allow use of PHI with individual authorization by the research subjects.
Any individual intending to conduct research involving human subjects, whether or not the research is supported by a grant, contract, or fellowship from any public or private agency, has the responsibility to file the approved IRB form following the procedures outlined in this handbook and in the application instructions.
Applications for review of human subjects research may be submitted by members of the faculty, staff, or administration of the University.
Students may submit applications with supervision of a mentor from the faculty, staff, or administration as provided in the section below on course-related and student-conducted research.
Individuals who are not students or employees of the University wishing to conduct research on the University campus require supervision and sponsorship by an appropriate University faculty, staff, or administration member who has demonstrated expertise in the area of proposed research.
All persons submitting applications for review by the IRB or DRB must provide evidence of completion of a human subjects education program approved by the IRB. Initial certification should be completed prior to submitting an application for review. Approval will not be granted unless a human subjects education program has been completed less than two years prior to submission of the application.
External Researchers are required to submit their application in University of Scranton format (IRB Form A, B or C) and include a copy of their Jurisdictional IRB approved protocol to the IRB Administrator, IMBM 203, University of Scranton, Scranton, PA 18510.
(a) External Researcher - a person not employed by the University of Scranton or otherwise affiliated with the University.
(b) Jurisdictional IRB - the primary IRB that has approved the external protocol. This is usually the external researcher's home institution.
(c) Faculty/Staff Sponsor - University of Scranton faculty, staff, or administrator who agrees to serve as the University contact person for the research.
(a) Applications not approved by a Jurisdictional IRB will not be reviewed by the University of Scranton IRB.
(b) Applications submitted by an External Researcher must have a University of Scranton Faculty/Staff Sponsor.
(c) Applications will be reviewed either administratively for expedited review (University of Scranton IRB Form A) or by full IRB review (University of Scranton IRB Form B or C) as appropriate.
(d) Recruitment may be approved for a period up to the expiration date of the Jurisdictional IRB approval
Student research and training activities involving human subjects may range from assignments taking place within the classroom to independent research projects. The instructor or advisor is ultimately responsible for training and supervising the student, assuring that student projects have been prepared in accordance with requirements and reviewed by the appropriate review board (DRB or IRB) and meet any departmental or other approval requirements.
Activities requiring IRB or DRB review:
(a) Student-generated research projects, including independent study, honors papers, theses, or other individual or small group projects. Application for IRB/DRB approval is submitted by the student(s) as the principal investigator(s) under the supervision of the mentor.
(b) Instructor-led class projects designed to teach research procedures and design - including projects where the instructor provides the protocol or where the class designs and generates the project. Application for IRB/DRB approval is submitted by the instructor.
(c) Classroom exercises conducted only with students in the class which involve the generating of sensitive information or entail more than minimal risk. Application for IRB/DRB approval is submitted by the instructor.
Activities not requiring IRB or DRB approval:
(a) Classroom exercises conducted only with members of the class, involving no more than minimal risk, and including no sensitive material.
(b) Journalism activities.
Form A and Form B applications (sections 5.06., 5.07.) may be submitted to the DRB by investigators whose departments have approved DRBs. Investigators in departments with DRBs may also submit Form A and Form B applications directly to the IRB.
Form C applications may only be reviewed by the IRB.
Information on dates of DRB meetings, deadlines for submission, and DRB forms is available from the appropriate DRB Chairperson.
Form A, Form B, and Form C applications (sections 5.06., 5.08.) may be submitted for review by the IRB.
The required number of copies as noted on each form are submitted to the IRB Administrator. Information on dates of IRB meetings, deadlines for submission, and forms is available from the IRB Administrator and on the website of the Office of Research and Sponsored Programs.
Form A applications (section 5.06.) shall be submitted to the IRB Administrator or to the appropriate DRB. Review and notification will be completed within 1 week of receipt.
An investigator from a department which has a DRB in place should submit the required number of copies of the Form A application to the DRB chair in accordance with the DRB procedures or may submit one complete electronic copy (all relevant sections compiled into one file - Adobe PDF or MS Word) and one hard copy with original signatures sent to the IRB Administrator. Applications submitted to the DRB will be reviewed in accordance with the procedures established by the DRB.
An investigator from a department with no DRB shall submit the application to the IRB Administrator. The IRB Administrator will review Form A applications in consultation as needed with the IRB Chair.
Form B applications (section 5.07) may be submitted to the DRB or the IRB.
One complete electronic copy of the Form B Application (all relevant sections compiled into one file - Adobe PDF or MS Word) and one hard copy with original signature/s must be submitted to the IRB Administrator at least 5 business days days prior to the date of the IRB meeting. Applications received too late to permit proper review will be deferred until the next regularly scheduled meeting.
Procedures for DRB submission are determined by each DRB in accordance with guidelines set forth by the IRB.
Form C applications (section 5.08) may be considered only by the IRB. One complete electronic copy of the Form C Application (all relevant sections compiled into one file - Adobe PDF or MS Word) and one hard copy with original signature/s must be submitted to the IRB Administrator at least 5 business days prior to the date of the IRB meeting. Applications received too late to permit proper review will be deferred until the next regularly scheduled meeting.
The IRB meets once a month in formal session during the academic year. As needed, the IRB may convene during intersession or summer sessions. The schedule of regular IRB meetings is posted on the Human Subjects webpage of the Office of Research and Sponsored Programs (ORSP) at the beginning of the academic year. Investigators may also contact the IRB Administrator or Chairperson for the dates of the monthly meetings. A convened meeting is a meeting of the IRB consisting of a quorum.
Minutes will be taken at all IRB meetings. Records will be retained by the IRB for at least three years.
A quorum is defined for IRB purposes as a majority of the members eligible to vote. An IRB member who is an investigator on a protocol for review at a convened meeting must absent him/herself from the meeting and may not be counted in the quorum for voting purposes.
No IRB member may participate in the board's initial or continuing review of any project in which the member has a conflicting interest, except to provide information requested by the IRB.
Form B and Form C applications for IRB review will be considered at a convened meeting (section 9.01) of the IRB.
Applications will be distributed by the IRB Administrator to all IRB members before the meeting date to permit adequate time for review and consideration.
Upon request of the IRB, an investigator may be asked to provide additional information or to appear in person before the committee to describe the proposed research and present a full explanation of risks and protection for the human subjects.
The IRB will decide by a majority of the members present (section 9.03):
(a) to approve the proposal,
(b) to approve the proposal with restrictions or conditions,
(c) to defer the proposal, pending changes in the application or receipt of additional information from the investigator or consultants to the IRB, OR
(d) to disapprove the proposal.
The IRB Administrator will inform the principal investigator in writing of the decision of the Board including any clarifications or changes which are required and/or recommended.
Applications requiring substantive clarification and/or change must be resubmitted to the IRB for further full board review.
The IRB may designate the IRB Chairperson, IRB Administrator, or a board member to review and either approve of the investigator's requested changes or require resubmission for review by the full board.
Adverse decisions may be appealed by re‑review of the proposal. Appeals will be heard only when the proposal has been revised and/or provides additional information.
In the event of severe time constraints, the IRB may conduct business by mail or e-mail if the research to be reviewed is no risk beyond everyday life. A project may be approved by a majority of members eligible to vote. However, if any IRB member requests Full IRB Review in a convened meeting, the application may not be approved until the IRB meets.
No application may be disapproved by any other procedure than vote at a convened meeting.
Records of the IRB are maintained by the IRB Administrator in the Office of Research Service. Records are retained for at least three years and in accordance with 45 CFR 46:115 (a - b).
Records of research protocols must be maintained for at least three years after completion of the research. These records contain the research proposal reviewed, scientific evaluations, approved sample consent documents, progress reports, reports of injuries to subjects, records of continuing review and copies of correspondence between the IRB and investigators.
Minutes of the IRB meetings contain the attendance at the meetings, actions taken, the vote on the actions, the basis for requiring changes in or disapproving research, full documentation of any waivers granted, and a written summary of the discussion of issues and their resolution.
The IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with IRB requirements or that has been associated with unexpected harm to subjects. A list of the reasons for any suspension or termination will be provided to the investigator, all appropriate department heads and the Director of Research.
The Investigator is responsible for reporting unanticipated problems or adverse events to the IRB Chairperson and the appropriate department chair.
Any instance of serious or continuing non-compliance with the IRB policies and procedures or the requirements or determinations of the IRB will be reported in the same manner.
Procedures for reporting scientific misconduct (including fabrication, falsification, plagiarism, unauthorized use of privileged information, violation of federal regulations, and retaliation against a person who has in good faith reported suspected or alleged misconduct) involving risk to human subjects or other people are listed in the University of Scranton Misconduct in Research Policy. Copies are available from the Office of Research and Sponsored Programs and on the ORSP website.
12.01. The IRB delegates review of certain categories of research to the DRB. Therefore the DRB functions in compliance with all the regulations and institutional policies applicable to the IRB. The DRB must submit written guidelines for approval by the IRB and may not review applications until the guidelines are approved.
The IRB has set the following standards for the functioning of DRBs and the preparation of written DRB Guidelines:
(a) Introduction: A description of the types of research involving human subjects which would normally be undertaken in the department, and which the department has sufficient experience to be able to review as no risk beyond everyday life, e.g., research covered under Forms A and B, but not under Form C.
(b) Ethical Standards: A statement of the ethical standards with which such activities must comply.
(c) Membership: A DRB should consist of a minimum of 4 members. A member of the DRB who is the investigator or faculty mentor or sponsor on a project under review cannot be present at the deliberations, counted in the quorum, or vote.
(d) Quorum: Attendance by a majority, but not less than 3, members eligible to vote constitutes a quorum.
(e) Meetings: Review of applications must take place in a convened meeting of the DRB with a quorum present. It is recommended that the DRB meet as needed, at least within 1 week of receipt of an application for review.
The DRB may designate one or two individual reviewers for Form A protocols. A designated reviewer may not review his/her own protocol.
(f) Records: Documentation of DRB actions must include
(1) Names of principal investigators and mentors, if applicable,
(2) Title of protocol,
(3) Type of application - faculty research, faculty led course assignment, student conducted course assignment, student independent research,
(4) Course number, if applicable,
(5) Category - Form A or Form B,
(6) Results of review, and
(7) Evidence that all investigators (faculty, students, and research assistants) have completed an approved human subjects education program in accordance with the IRB guidelines.
(g) Procedure for Submission of Applications: Outline the procedure to be followed by the investigators. IRB/DRB forms A and B must utilized.
(h) Procedure for Review of Applications: Unanimous agreement of the DRB members eligible to vote at a meeting is required for approval of a Form B application. Form A applications may be reviewed as noted above (section 12.02.(e)).
(i) Actions: Following review, the DRB may
(1) approve the application,
(2) request specific changes and resubmission by the investigator for further DRB review,
(3) notify the investigator of the concerns of the DRB and request that the investigator resubmit the application the application to the IRB, OR
(4) notify the investigator that the application does not meet criteria for DRB review and must be submitted on Form C for IRB.
Report of DRB actions should be sent to the IRB Administrator within one week of the DRB meeting, following the outline for DRB documentation above.
Applications must be submitted directly to the IRB for research:
(a) Involving risk beyond everyday life (section 5.03) to human subjects,
(b) To be submitted for extramural funding or support,
(c) Involving any vulnerable subjects (section 7.02), except for the use of pre-existing data with no identifiers,
(d) Involving deception (section 5.05),
(e) Requiring waivers of any part of informed consent (section 7.07.03), unless approval authorization is granted by the IRB for specific circumstances,
(f) To be conducted by an investigator from outside of, but involving, the University,
(g) Which does not fall within a DRB's guidelines,
(h) For which the IRB provides notice to the investigator or department that the IRB is exercising its oversight responsibility and requires IRB review and approval, or
(i) For which an investigator requests IRB review in addition to, or in substitution for, the departmental review process, even if this activity falls within the departmental guidelines.